PDF(Pubmed)
Abstract：
OBJECTIVE: Few studies have focused on the late adverse events after oncologic treatment in pelvic cancer patients. Here, the treatment effect/interventions were studied on late side effects as GI, sexual, and urinary symptoms in pelvic cancer patients who visited a highly specialized rehabilitation clinic in Linköping.
METHODS: This retrospective longitudinal cohort study included 90 patients who had at least one visit at the rehabilitation clinic for late adverse events at Linköping University hospital between 2013 to 2019. The toxicity of the adverse events was analyzed by using the common terminology criteria for adverse events (CTCAE).
RESULTS: By comparing the toxicity of symptoms between visits 1 and 2, we showed that the GI symptoms decreased with 36.6% (P = 0.013), the sexual symptoms with 18.3% (P < 0.0001), and urinary symptoms with 15.5% (P = 0.004). Patients who received bile salt sequestrant had a significant improvement in grade of GI symptoms as diarrhea/fecal incontinence at visit 2 compared to visit 1 where 91.3% were shown to have a treatment effect (P = 0.0034). The sexual symptoms (vaginal dryness/pain) significantly improved due to local estrogens between visits 1 and 2 where 58.1% had a reduction of symptoms (P = 0.0026).
CONCLUSIONS: The late side effects as GI, sexual, and urinary symptoms was significantly reduced between visits 1 and 2 at the specialized rehabilitation center in Linköping. Bile salt sequestrants and local estrogens are effective treatments for side effects as diarrhea and vaginal dryness/pain.
METHODS: This retrospective longitudinal cohort study included 90 patients who had at least one visit at the rehabilitation clinic for late adverse events at Linköping University hospital between 2013 to 2019. The toxicity of the adverse events was analyzed by using the common terminology criteria for adverse events (CTCAE).
RESULTS: By comparing the toxicity of symptoms between visits 1 and 2, we showed that the GI symptoms decreased with 36.6% (P = 0.013), the sexual symptoms with 18.3% (P < 0.0001), and urinary symptoms with 15.5% (P = 0.004). Patients who received bile salt sequestrant had a significant improvement in grade of GI symptoms as diarrhea/fecal incontinence at visit 2 compared to visit 1 where 91.3% were shown to have a treatment effect (P = 0.0034). The sexual symptoms (vaginal dryness/pain) significantly improved due to local estrogens between visits 1 and 2 where 58.1% had a reduction of symptoms (P = 0.0026).
CONCLUSIONS: The late side effects as GI, sexual, and urinary symptoms was significantly reduced between visits 1 and 2 at the specialized rehabilitation center in Linköping. Bile salt sequestrants and local estrogens are effective treatments for side effects as diarrhea and vaginal dryness/pain.
摘要：
目的：很少有研究关注盆腔癌患者肿瘤治疗后的晚期不良事件。这里,治疗效果/干预措施在晚期副作用如GI，性,和盆腔癌患者的泌尿系统症状，他们去了林雪平的一家高度专业化的康复诊所。
方法：这项回顾性纵向队列研究包括2013年至2019年在林雪平大学医院康复诊所就诊至少一次的患者。使用常见的不良事件术语标准（CTCAE）分析不良事件的毒性。
结果：通过比较第1次和第2次就诊之间症状的毒性，我们发现胃肠道症状减少了36.6％（P=0.013），性症状占18.3%(P<0.0001),尿路症状占15.5%(P=0.004)。与第1次就诊相比，接受胆汁盐螯合剂的患者在第2次就诊时的胃肠道症状（腹泻/大便失禁）等级显着改善，其中91.3％显示具有治疗效果（P=0.0034）。由于在第1次和第2次就诊之间的局部雌激素，性症状（阴道干燥/疼痛）显着改善，其中58.1％的症状减轻（P=0.0026）。
结论：作为胃肠道的晚期副作用，性,在林雪平专业康复中心的第1次和第2次就诊之间,泌尿系统症状显著减轻.胆汁盐螯合剂和局部雌激素是治疗腹泻和阴道干燥/疼痛等副作用的有效方法。
方法：这项回顾性纵向队列研究包括2013年至2019年在林雪平大学医院康复诊所就诊至少一次的患者。使用常见的不良事件术语标准（CTCAE）分析不良事件的毒性。
结果：通过比较第1次和第2次就诊之间症状的毒性，我们发现胃肠道症状减少了36.6％（P=0.013），性症状占18.3%(P<0.0001),尿路症状占15.5%(P=0.004)。与第1次就诊相比，接受胆汁盐螯合剂的患者在第2次就诊时的胃肠道症状（腹泻/大便失禁）等级显着改善，其中91.3％显示具有治疗效果（P=0.0034）。由于在第1次和第2次就诊之间的局部雌激素，性症状（阴道干燥/疼痛）显着改善，其中58.1％的症状减轻（P=0.0026）。
结论：作为胃肠道的晚期副作用，性,在林雪平专业康复中心的第1次和第2次就诊之间,泌尿系统症状显著减轻.胆汁盐螯合剂和局部雌激素是治疗腹泻和阴道干燥/疼痛等副作用的有效方法。
